Antagonizing CD105 enhances radiation sensitivity in prostate cancer

Radiation therapy is the primary intervention for nearly half of the patients with localized advanced prostate cancer and standard of care for recurrent disease following surgery. The development of radiation-resistant disease is an obstacle for nearly 30–50% of patients undergoing radiotherapy. A b...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhav, Anisha, Andres, Allen, Duong, Frank, Mishra, Rajeev, Haldar, Subhash, Liu, Zhenqiu, Angara, Bryan, Gottlieb, Roberta, Zumsteg, Zachary S., Bhowmick, Neil A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085281/
https://www.ncbi.nlm.nih.gov/pubmed/29717261
http://dx.doi.org/10.1038/s41388-018-0278-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085281/
https://www.ncbi.nlm.nih.gov/pubmed/29717261
http://dx.doi.org/10.1038/s41388-018-0278-0

Ejemplares similares